ASCO GU 2022: First Results of the MAGNITUDE: Phase 3 Study of Niraparib With Abiraterone Acetate and Prednisone As First-Line Therapy in Patients With mCRPC With and Without HRR Gene Alterations
www.urotoday.com/conference-highlights/asco-gu-2022/asco-gu-2022-prostate-cancer/135402-asco-gu-2022-first-results-of-the-magnitude-phase-3-study-of-niraparib-with-abiraterone-acetate-and-prednisone-as-first-line-therapy-in-patients-with-mcrpc-with-and-without-hrr-gene-alterations.html
Feb 19, 2022
10
Determining the diagnostic value of PSMA-PET/CT imaging in patients with persistent high prostate specific antigen levels and negative prostate biopsies
www.sciencedirect.com/science/article/pii/S1078143921003112
Feb 8, 2022
11
ASCO GU 2021: Concordance of BRCA1 and BRCA2, and ATM Mutations Identified in Matched Tumor Tissue and ctDNA in Men mCRPC Screened in the PROfound Study
www.urotoday.com/conference-highlights/asco-gu-2021/prostate-cancer/128072-asco-gu-2021-concordance-of-brca1-brca2-brca-and-atm-mutations-identified-in-matched-tumor-tissue-and-ctdna-in-men-mcrpc-screened-in-the-profound-study.html
Jul 2, 2021
1
PARP Inhibitors in Prostate Cancer
www.urotoday.com/library-resources/advanced-prostate-cancer/122683-parp-inhibitors-in-prostate-cancer.html
Jun 11, 2021
3
CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors | JCO Precision Oncology
ascopubs.org/doi/full/10.1200/PO.19.00399
May 12, 2021
1
CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors | JCO Precision Oncology
ascopubs.org/doi/full/10.1200/PO.19.00399?utm_source=TrendMD&utm_medium=cpc&utm_campaign=JCO_PO_TrendMD_0
May 12, 2021
1
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
link.springer.com/article/10.1007/s40487-020-00119-z
Mar 6, 2021
1
ASCO GU 2021: Discussion: Molecular Correlates of Response to Apalutamide in nmCRPC and Final Results from ACIS, Androgen Annihilation with Abiraterone and Apalutamide in Chemo-Naïve mCRPC
www.urotoday.com/conference-highlights/asco-gu-2021/prostate-cancer/127872-asco-gu-2021-discussion-molecular-correlates-of-response-to-apalutamide-in-nmcrpc-and-final-results-from-acis-androgen-annihilation-with-abiraterone-and-apalutamide-in-chemo-naive-mcrpc.html
Feb 18, 2021
8
ASCO GU 2021: Survival Outcomes in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC): A Real-World Evidence Study
www.urotoday.com/conference-highlights/asco-gu-2021/prostate-cancer/127844-asco-gu-2021-survival-outcomes-in-patients-with-metastatic-castration-sensitive-prostate-cancer-mcspc-a-real-world-evidence-study.html
Feb 18, 2021
2
ASCO GU 2021: Multi-Institutional Evaluation of the Clinical Outcomes and Genomic Correlates of African Americans with Metastatic Castration-Sensitive Prostate Cancer
www.urotoday.com/conference-highlights/asco-gu-2021/prostate-cancer/127819-asco-gu-2021-multi-institutional-evaluation-of-the-clinical-outcomes-and-genomic-correlates-of-african-americans-with-metastatic-castration-sensitive-prostate-cancer.html
Feb 18, 2021
2
RemNote – Your Thinking and Learning Workspace.
www.remnote.io/document/60271abb877de9d3228e4010/8pSxrD7ADwj3ZFGTF
Feb 15, 2021
1
PII: S0046-8177(00)80035-0
x-pdf:da4c727bab9374518659b679eb01f375
Feb 14, 2021
1
Androgen receptor status of lymph node metastases from prostate cancer
onlinelibrary.wiley.com/doi/abs/10.1002/(SICI)1097-0045(199602)28:2%3C129::AID-PROS9%3E3.0.CO;2-B
Feb 13, 2021
1
Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients
www.sciencedirect.com/science/article/abs/pii/S0046817700800350
Feb 13, 2021
1
Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier
www.sciencedirect.com/science/article/pii/S2214388218300730
Feb 13, 2021
4
Molecular pathology of prostate cancer
jcp.bmj.com/content/58/7/673
Jan 28, 2021
1
SIU 2019: Timing of ADT in the Era of STAMPEDE and LATITUDE
www.urotoday.com/conference-highlights/siu-2019/siu-2019-prostate/115826-siu-2019-timing-of-adt-in-the-era-of-stampede-and-latitude.html
Jan 25, 2021
2
Advances in Treatment for Metastatic Hormone Sensitive Prostate Cancer: With So Many Options, Can We Really Go Wrong?
www.urotoday.com/center-of-excellence/mhspc/from-the-editor/114565-advances-in-treatment-for-metastatic-hormone-sensitive-prostate-cancer-mhspc-with-so-many-options-can-we-really-go-wrong.html
Jan 20, 2021
3
Impact of Academic Collaborations in mHSPC Trial: ENZAMET - Chris Sweeney
www.urotoday.com/video-lectures/asco-2019/video/1324-impact-of-academic-collaborations-in-mhspc-trial-enzamet-chris-sweeney.html
Jan 20, 2021
11
ASCO GU 2020: Treatment Selection in mHSPC: Considerations Now and Downstream in an Evolving Therapeutic Landscape
www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-prostate-cancer/119166-asco-gu-2020-treatment-selection-in-cspc-considerations-now-and-downstream-in-an-evolving-therapeutic-landscape-discussion-of-abstracts-82-and-162.html
Jan 20, 2021
5
Ileal Conduit Versus Cutaneous Ureterostomy After Radical Cystectomy - Full Text View - ClinicalTrials.gov
clinicaltrials.gov/ct2/show/NCT04610385
Jan 17, 2021
1
ASCO 2020: HERO Phase III Trial: Results Comparing Relugolix, an Oral GnRH Receptor Antagonist, versus Leuprolide Acetate for Advanced Prostate Cancer
www.urotoday.com/conference-highlights/asco-2020/asco-2020-prostate-cancer/121804-asco-2020-hero-phase-iii-trial-results-comparing-relugolix-an-oral-gnrh-receptor-antagonist-versus-leuprolide-acetate-for-advanced-prostate-cancer.html
Jan 17, 2021
1
ASCO GU 2020: Efficacy of Olaparib by Prior Taxane Use in Patients with Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Repair Gene Alterations: The PROfound Trial
www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-prostate-cancer/119414-asco-gu-2020-profound-efficacy-of-olaparib-by-prior-taxane-use-in-patients-with-metastatic-castration.html
Jan 9, 2021
1
SUO 2020: Results from the PROfound Study, A New Second Line Therapy for mCRPC
www.urotoday.com/conference-highlights/suo-2020/suo-2020-gu-malignancies-prostate/126345-suo-2020-results-from-the-profound-study-a-new-second-line-therapy-for-mcrpc.html
Jan 9, 2021
6
PI-RADS 2.1 - Image Interpretation: The Most Important Updates and Their Clinical Implications.
www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/126809-pi-rads-2-1-image-interpretation-the-most-important-updates-and-their-clinical-implications.html
Dec 25, 2020
3
Clinical impact of PSMA PET in biochemically recurrent prostate cancer; a review of the literature
link.springer.com/article/10.1007/s13629-020-00296-6
Dec 23, 2020
1
Treatment Outcomes from 68Ga-PSMA PET/CT–Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET
scite.ai/reports/treatment-outcomes-from68ga-psma-pet-ct-informed-salvage-vJGwdZ4
Dec 23, 2020
1
APCCC 2019: How to Treat Men with Newly Diagnosed cN1 cM0 Prostate Cancer - Surgery Options
www.urotoday.com/conference-highlights/apccc-2019/114595-apccc-2019-how-to-treat-men-with-newly-diagnosed-cn1-cm0-prostate-cancer-surgery-options.html
Dec 20, 2020
4
FDA Approves First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer
www.fda.gov/news-events/press-announcements/fda-approves-first-psma-targeted-pet-imaging-drug-men-prostate-cancer
Dec 19, 2020
1
ASCO GU 2020: Challenging Cases in Prostate Cancer – Case 1: PSMA PET/CT Imaging
www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-prostate-cancer/119153-asco-gu-2020-challenging-cases-in-prostate-cancer-case-1.html
Dec 18, 2020
1
The Impact of Adding Sentinel Node Biopsy to Extended Pelvic Lymph Node Dissection on Biochemical Recurrence in Prostate Cancer Patients Treated with Robot-Assisted Radical Prostatectomy
jnm.snmjournals.org/content/59/2/204
Dec 18, 2020
2
RESTORE: A single-arm, open-label phase II trial of bipolar androgen therapy (BAT) in men with metastatic castration resistant prostate cancer (mCRPC)—A comparison of post-abiraterone (Abi) versus post-enzalutamide (Enza) patients (Pts). | Journal of Clinical Oncology
ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.5576
Nov 22, 2020
1
RESTORE: A single-arm, open-label phase II trial of bipolar androgen therapy (BAT) in men with metastatic castration resistant prostate cancer (mCRPC)—A comparison of post-abiraterone (Abi) versus post-enzalutamide (Enza) patients (Pts). | Journal of Clinical Oncology
ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.5576?af=R
Nov 22, 2020
1
Accuracy of 68Ga-PSMA-11 for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: A multicenter prospective phase III imaging study. | Journal of Clinical Oncology
ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.5502
Nov 9, 2020
2
Extended versus limited pelvic lymphadenectomy during radical prostatectomy for intermediate- and high-risk prostate cancer: Early outcomes from a randomized controlled phase III study. | Journal of Clinical Oncology
ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.5018
Nov 7, 2020
1
EAU 2020: Continence Following Robot-Assisted and Conventional Laparoscopic Radical Prostatectomy– Results of a Prospective, Randomized, Multicenter, Patient Blinded Study
www.urotoday.com/conference-highlights/eau-2020/prostate-cancer/123156-eau-2020-continence-following-robot-assisted-and-conventional-laparoscopic-radical-prostatectomy-results-of-a-prospective-randomized-multicenter-patient-blinded-study.html
Nov 6, 2020
1
Non-muscle Invasive Bladder Cancer: Overcoming Diagnostic and Therapeutic Challenges
www.urotoday.com/journal/everyday-urology-oncology-insights/articles/125180-non-muscle-invasive-bladder-cancer-overcoming-diagnostic-and-therapeutic-challenges.html
Nov 1, 2020
3
The Evolving Role of Prostate-Specific Membrane Antigen–Based Diagnostics and Therapeutics in Prostate Cancer | American Society of Clinical Oncology Educational Book
ascopubs.org/doi/10.1200/EDBK_239187
Oct 31, 2020
2
The Evolving Role of Prostate-Specific Membrane Antigen–Based Diagnostics and Therapeutics in Prostate Cancer | American Society of Clinical Oncology Educational Book
ascopubs.org/doi/10.1200/EDBK_239187?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
Oct 31, 2020
2
Treatment Outcomes from 68Ga-PSMA PET/CT–Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET
jnm.snmjournals.org/content/58/12/1972.long
Oct 30, 2020
1
Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial.
www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/123841-pelvic-lymph-node-staging-with-18f-dcfpyl-pet-ct-prior-to-extended-pelvic-lymph-node-dissection-in-primary-prostate-cancer-the-salt-trial.html
Oct 26, 2020
1
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer | NEJM
www.nejm.org/doi/10.1056/NEJMoa022148
Oct 20, 2020
3
The Zettelkasten Method: Examples to help you get started.
medium.com/@rebeccawilliams9941/the-zettelkasten-method-examples-to-help-you-get-started-8f8a44fa9ae6
Oct 10, 2020
1
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
www.cell.com/cell/fulltext/S0092-8674(17)31056-5
Oct 9, 2020
1
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
www.cell.com/cell/fulltext/S0092-8674(17)31056-5?_returnURL=https://linkinghub.elsevier.com/retrieve/pii/S0092867417310565?showall=true
Oct 9, 2020
1
Lynch Syndrome
www.cancer.net/cancer-types/lynch-syndrome
Oct 5, 2020
4
Lynch Syndrome | CDC
www.cdc.gov/genomics/disease/colorectal_cancer/lynch.htm
Oct 5, 2020
3
Study simplifies bladder cancer molecular subtypes
www.mdedge.com/hematology-oncology/article/214920/genitourinary-cancer/study-simplifies-bladder-cancer-molecular
Oct 3, 2020
1
Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care?
www.ncbi.nlm.nih.gov/pmc/articles/PMC3553558/
Aug 28, 2020
1